TGTX
VENTE TOTALE: 5 000 titres (~274 800,00 $ US)
- Insiders
- Charney Laurence N
- Total bought
- —
- Total sold
- $274,800
- Last activity
- 2026-09-10
- Last synced
-
2026-09-16 10:10:23
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signal Scored 2026-09-16
TGTX presents a compelling financial turnaround story with strong improving fundamentals (liquidity 75, fundamental trend 85) and meaningful M&A catalyst momentum driven by Briumvi's commercial growth and subcutaneous…
The first sentence of the analysis written for TGTX on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | |
| Ebit Margin | 21.8% | 15.1% | 11.0% | -7670.4% | -5119.8% | |
| Ebitda Margin | 21.8% | 15.2% | 11.2% | -7651.9% | -5112.4% | |
| Operating Profit Margin | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | |
| Pretax Profit Margin | 17.4% | 7.8% | 5.6% | -8036.3% | -5204.1% | |
| Continuous Operations Profit Margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | |
| Net Profit Margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | |
| Bottom Line Profit Margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | |
| Current Ratio | 4.102 | 6.246 | 5.919 | 3.163 | 5.062 | |
| Quick Ratio | 3.285 | 5.028 | 5.177 | 3.163 | 5.062 | |
| Solvency Ratio | 1.078 | 0.067 | 0.077 | -1.654 | -2.440 | |
| Cash Ratio | 0.515 | 1.984 | 1.730 | 1.923 | 4.571 | |
| Price To Earnings Ratio | 9.616 | 188.125 | 191.265 | -8.103 | -7.224 | |
| Price To Earnings Growth Ratio | 0.005 | 2.376 | -1.802 | 0.182 | -0.833 | |
| Forward Price To Earnings Growth Ratio | 0.005 | 2.376 | -1.802 | 0.182 | -0.833 | |
| Price To Earnings Diluted Ratio | 10.762 | 200.667 | 200.234 | -8.103 | -7.224 | |
| Price To Earnings Diluted Growth Ratio | 0.006 | 2.646 | -1.892 | 0.182 | -0.833 | |
| Price To Book Ratio | 6.639 | 19.671 | 15.106 | 27.343 | 10.593 | |
| Price To Sales Ratio | 6.981 | 13.295 | 10.376 | 575.194 | 375.577 | |
| Price To Free Cash Flow Ratio | -172.180 | -107.836 | -77.184 | -9.092 | -8.486 | |
| Price To Operating Cash Flow Ratio | -173.667 | -107.956 | -77.184 | -9.093 | -8.498 | |
| Debt To Assets Ratio | 0.245 | 0.439 | 0.336 | 0.429 | 0.208 | |
| Debt To Equity Ratio | 0.402 | 1.141 | 0.690 | 1.418 | 0.333 | |
| Debt To Capital Ratio | 0.287 | 0.533 | 0.408 | 0.586 | 0.250 | |
| Long Term Debt To Capital Ratio | 0.281 | 0.524 | 0.384 | 0.548 | 0.220 | |
| Financial Leverage Ratio | 1.641 | 2.598 | 2.053 | 3.304 | 1.601 | |
| Working Capital Turnover Ratio | 1.294 | 0.889 | 1.232 | 0.015 | 0.017 | |
| Operating Cash Flow Ratio | -0.161 | -0.447 | -0.585 | -3.311 | -4.522 | |
| Operating Cash Flow Sales Ratio | -0.040 | -0.123 | -0.134 | -63.257 | -44.197 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.009 | 1.001 | 1.000 | 1.000 | 1.001 | |
| Debt Service Coverage Ratio | 17.074 | 1.985 | 2.038 | -20.911 | -51.712 | |
| Interest Coverage Ratio | 4.614 | 1.745 | 1.636 | -21.422 | -61.151 | |
| Short Term Operating Cash Flow Coverage Ratio | -23.728 | 0.000 | 0.000 | 0.000 | -303.214 | |
| Operating Cash Flow Coverage Ratio | -0.095 | -0.160 | -0.284 | -2.121 | -3.740 | |
| Capital Expenditure Coverage Ratio | -115.757 | -900.378 | 0.000 | -12,583.571 | -737.242 | |
| Dividend Paid And Capex Coverage Ratio | -115.757 | -900.378 | 0.000 | -12,583.571 | -737.242 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.370 | 89.132 | 93.581 | -7.427 | -6.704 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 83.7% | ▼-4.6% | ▼-5.3% |
| Ebit Margin | 21.8% | ▲6.7% | ▲2570.2% |
| Ebitda Margin | 21.8% | ▲6.6% | ▲2565.0% |
| Operating Profit Margin | 20.0% | ▲7.3% | ▲2610.3% |
| Pretax Profit Margin | 17.4% | ▲9.7% | ▲2659.3% |
| Continuous Operations Profit Margin | 72.6% | ▲65.5% | ▲2703.6% |
| Net Profit Margin | 72.6% | ▲65.5% | ▲2703.6% |
| Bottom Line Profit Margin | 72.6% | ▲65.5% | ▲2703.6% |
| Current Ratio | 4.102 | ▼-2.143 | ▼-0.796 |
| Quick Ratio | 3.285 | ▼-1.742 | ▼-1.058 |
| Solvency Ratio | 1.077 | ▲1.011 | ▲1.652 |
| Cash Ratio | 0.515 | ▼-1.469 | ▼-1.630 |
| Price To Earnings Ratio | 9.616 | ▼-178.509 | ▼-65.120 |
| Price To Earnings Growth Ratio | 0.005 | ▼-2.371 | ▲0.019 |
| Forward Price To Earnings Growth Ratio | 0.005 | ▼-2.371 | ▲0.019 |
| Price To Earnings Diluted Ratio | 10.762 | ▼-189.905 | ▼-68.505 |
| Price To Earnings Diluted Growth Ratio | 0.006 | ▼-2.639 | ▼-0.016 |
| Price To Book Ratio | 6.639 | ▼-13.032 | ▼-9.232 |
| Price To Sales Ratio | 6.981 | ▼-6.314 | ▼-189.304 |
| Price To Free Cash Flow Ratio | -172.180 | ▼-64.344 | ▼-97.224 |
| Price To Operating Cash Flow Ratio | -173.667 | ▼-65.712 | ▼-98.388 |
| Debt To Assets Ratio | 0.245 | ▼-0.194 | ▼-0.086 |
| Debt To Equity Ratio | 0.402 | ▼-0.739 | ▼-0.395 |
| Debt To Capital Ratio | 0.287 | ▼-0.246 | ▼-0.126 |
| Long Term Debt To Capital Ratio | 0.281 | ▼-0.243 | ▼-0.111 |
| Financial Leverage Ratio | 1.641 | ▼-0.957 | ▼-0.599 |
| Working Capital Turnover Ratio | 1.294 | ▲0.405 | ▲0.604 |
| Operating Cash Flow Ratio | -0.161 | ▲0.286 | ▲1.644 |
| Operating Cash Flow Sales Ratio | -0.040 | ▲0.083 | ▲21.510 |
| Free Cash Flow Operating Cash Flow Ratio | 1.009 | ▲0.007 | ▲0.006 |
| Debt Service Coverage Ratio | 17.074 | ▲15.089 | ▲27.379 |
| Interest Coverage Ratio | 4.614 | ▲2.869 | ▲19.530 |
| Short Term Operating Cash Flow Coverage Ratio | -23.728 | ▼-23.728 | ▲41.660 |
| Operating Cash Flow Coverage Ratio | -0.095 | ▲0.065 | ▲1.185 |
| Capital Expenditure Coverage Ratio | -115.757 | ▲784.621 | ▲2751.633 |
| Dividend Paid And Capex Coverage Ratio | -115.757 | ▲784.621 | ▲2751.633 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.370 | ▼-55.762 | ▼-7.020 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.30B | $4.37B | $2.42B | $1.60B | $2.51B | |
| Enterprise value | $4.48B | $4.45B | $2.44B | $1.58B | $2.29B | |
| EV / Sales | 7.28x | 13.52x | 10.45x | 568.28x | 342.71x | |
| EV / Op. cash flow | -181.00x | -109.78x | -77.75x | -8.98x | -7.75x | |
| EV / Free cash flow | -179.45x | -109.66x | -77.75x | -8.98x | -7.74x | |
| EV / EBITDA | 33.37x | 89.13x | 93.58x | -7.43x | -6.70x | |
| Net debt / EBITDA | 1.35x | 1.48x | 0.68x | 0.09x | 0.64x | |
| Current ratio | 4.10x | 6.25x | 5.92x | 3.16x | 5.06x | |
| Income quality | -0.06x | -1.73x | -2.48x | 0.89x | 0.85x | |
| Graham number | $18 | $2 | $2 | — | — | |
| Graham net-net | $0 | $1 | $1 | $0 | $1 | |
| Tax burden | 416.4% | 91.4% | 97.0% | 100.0% | 100.0% | |
| Interest burden | 80.1% | 51.6% | 50.9% | 104.8% | 101.6% | |
| Working capital | $477.0M | $475.7M | $264.2M | $115.1M | $265.6M | |
| Invested capital | $483.3M | $482.8M | $273.2M | $126.7M | $277.4M | |
| Return on assets | 42.1% | 4.0% | 3.8% | -115.6% | -91.7% | |
| Operating ROA | 15.0% | 9.2% | 7.9% | -76.2% | -68.6% | |
| Return on tangible assets | 42.1% | 4.0% | 3.9% | -116.1% | -91.9% | |
| Return on equity | 69.0% | 10.5% | 7.9% | -382.0% | -146.8% | |
| Return on invested capital | 13.5% | 7.8% | 7.2% | -153.8% | -108.9% | |
| Return on capital employed | 13.6% | 8.6% | 7.5% | -155.5% | -109.7% | |
| Earnings yield | 10.4% | 0.5% | 0.5% | -14.0% | -13.9% | |
| Free cash flow yield | -0.6% | -0.9% | -1.3% | -11.0% | -11.8% | |
| Capex / Op. cash flow | -0.9% | -0.1% | 0.0% | -0.0% | -0.1% | |
| Capex / Depreciation | 362.7% | 16.1% | 0.0% | 2.7% | 81.2% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.5% | 6.0% | |
| SG&A / Sales | 37.7% | 46.9% | 52.5% | 3428.5% | 1914.9% | |
| R&D / Sales | 26.0% | 28.7% | 32.6% | 4501.0% | 3327.5% | |
| Stock comp / Sales | 10.5% | 12.9% | 16.2% | 688.9% | 916.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.2% | 0.4% | 0.2% | |
| Days sales outstanding | 181d | 143d | 80d | 0d | 76d | |
| Days payables outstanding | 390d | 0d | 0d | 0d | 0d | |
| Operating cycle | 636d | 1191d | 1108d | 0d | 76d | |
| Cash conversion cycle | 247d | 1191d | 1108d | 0d | 76d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-1.6%EV / Sales ▼-46.2%EV / EBITDA ▼-62.6%EV / Op. cash flow ▼-71.220Earnings yield ▲+0.099Graham number ▲+15.340
Profitability
Return on equity ▲+0.585Return on assets ▲+0.380Return on invested capital ▲+0.057Return on capital employed ▲+0.050Operating ROA ▲+0.058Income quality ▲+1.677Tax burden ▲+3.250
Efficiency
Days sales outstanding ▲+37.691Days payables outstanding n/aOperating cycle ▼-554.750Cash conversion cycle ▼-944.372Capex / Sales +0.000R&D / Sales ▼-0.027
Balance-sheet strength
Current ratio ▼-2.143Net debt / EBITDA ▼-0.128Working capital ▲+1324000.000Invested capital ▲+451000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+71.2%EV / Sales ▼-97.9%EV / EBITDA ▲+597.8%EV / Op. cash flow ▼-173.243Earnings yield ▲+0.243
Profitability
Return on equity ▲+2.158Return on assets ▲+1.338Return on invested capital ▲+1.224Return on capital employed ▲+1.233Operating ROA ▲+0.836Income quality ▼-0.905Tax burden ▲+3.164
Efficiency
Days sales outstanding ▲+105.216Days payables outstanding n/aOperating cycle ▲+560.356Cash conversion cycle ▲+170.733Capex / Sales ▼-0.060R&D / Sales ▼-33.015
Balance-sheet strength
Current ratio ▼-0.960Net debt / EBITDA ▲+0.709Working capital ▲+211423000.000Invested capital ▲+205834000.000Intangibles / Total assets ▼-0.002
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-09-08 | Chris Jacobs | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-09-15 California State Teachers Retirement System Acquires 9,198,333 Shares of TG Therapeutics, Inc. $TGTX California State Teachers Retirement System lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 5,233.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 9,374,083 shares of the biopharmaceutical company''s stock after acquiring an additional 9,198,333 shares during the period. California State Teachers
- 2026-09-10 TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
- 2026-09-03 TG Therapeutics to Participate in the Cantor Global Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
- 2026-09-02 TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue? TG Therapeutics (TGTX) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-26 TG Therapeutics: Briumvi''s Peak May Be Far Away (Rating Upgrade) TG Therapeutics, Inc.''s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
- 2026-08-23 235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company''s stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%
- 2026-08-22 TG Therapeutics: Briumvi''s Growth Attracts Buyout Rumors Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi''s growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
- 2026-08-13 Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX Bank of America Corp DE lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 71.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,302 shares of the biopharmaceutical company''s stock after buying an additional 610,195 shares
- 2026-08-13 Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX Assenagon Asset Management S.A. decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 82.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,681 shares of the biopharmaceutical company''s stock after selling 418,373 shares during the period. Assenagon Asset
- 2026-08-11 Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $63.00 TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average rating of "Hold" from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average